Benzyl (2S,3aR,7aS)-octahydroindole-2-carboxylate hydrochloride

We are Benzyl (2S,3aR,7aS)-octahydroindole-2-carboxylate hydrochloride CAS:87679-38-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Benzyl (2S,3aR,7aS)-octahydroindole-2-carboxylate hydrochloride
CAS.NO:87679-38-7
Synonyms:Benzyl (2S,3aR,7aS)-octahydroindole-2-carboxylate hydrochloride
Benzyl-(2s,3ar,7as)-1h-Octahydroindole-2-Carboxylate HCl
BENZYL-2S,3AR,7AS-1H-OCTAHYDROINDOLE-2-CARBOXYLATE HYDROCHLORIDE
 
Physical and Chemical Properties:
Density 1.103g/cm3
Boiling Point 376.287ºC at 760 mmHg
Molecular Formula C16H21NO2
Molecular Weight 259.34300
Flash Point 181.372ºC
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Trandolaprilum(CAS:87679-37-6).

Benzyl (2S,3aR,7aS)-octahydroindole-2-carboxylate hydrochloride


Related News: China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.13007-50-6 On the other hand, the company has many new products in recent years, including Duqiao Base, Yancheng United Chemical and Dezhou United Chemical. These new products are mostly customized products with strong profitability, which has improved the gross profit margin of the industrial business.68037-59-2 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carbonitrile Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.

Related Products
Product Name
N-(4-Chloro-3-cyano-7-ethoxy-6-quinolinyl)acetamide View Details
(2S)-1-N-(2-aminoethyl)-3-(4-ethoxyphenyl)propane-1,2-diamine,trihydrochloride View Details
2-Fluoro-5-iodobenzonitrile View Details
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]glycylglycylglycylglycine manufacturer 2-Bromo-3-Fluoro-4-Picoline manufacturer 2-Propoxyethyl Chloride manufacturer 2-Bromophenol manufacturer 2-Chloro-4-iodopyridine manufacturer